Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

45891 - 45900 of 58470 results found

Viral dynamics of SARS-CoV-2 in immunocompromised patients

Date
Sunday, May 14, 2023 - 4:00 AM
Description
CONCLUSIONS: Half of the patients in this cohort had no viable virus after five days and only two patients had replicative virus after 15 days. This could indicate that the current CDC-recommendations of an isolation period of 20 days for

Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections

Date
Sunday, May 14, 2023 - 4:00 AM
Description
CONCLUSION: Rituximab in patients with autoimmune diseases reduces humoral responses but does not avoid the development of T cell responses to SARS-CoV-2 vaccination, which remain present after a booster dose. A steady cellular immunity appears to be